Local Ketamine Instillation for Postoperative Analgesia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02642497 |
Recruitment Status :
Completed
First Posted : December 30, 2015
Last Update Posted : January 4, 2017
|
Sponsor:
Assiut University
Information provided by (Responsible Party):
Ahmad Mohammad Abd El-Rahman, Assiut University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study aims at exploring the analgesic efficacy, and safety of Ketamine instillation into the wound of total thyroidectomy compared to placebo,and to systemic ketamine administration (I.M. injection of the same dose) with respect to postoperative VAS, first request of analgesia, total opioid consumption, and with respect to possible side effects.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Postoperative Pain | Drug: intra-wound instillation of ketamine Drug: intra-wound instillation of normal saline Drug: systemic administration of ketamine | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 90 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Efficacy of Postoperative Analgesia Offered by Local Ketamine Wound Instillation Following Total Thyroidctomy; a Randomized, Double-blind, Controlled-clinical Trial |
Study Start Date : | August 2015 |
Actual Primary Completion Date : | February 2016 |
Actual Study Completion Date : | December 2016 |
Resource links provided by the National Library of Medicine

Drug Information available for:
Ketamine
Arm | Intervention/treatment |
---|---|
Active Comparator: local ketamine group
intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure, with closure of suction drain tube for 30 min. postoperatively.
|
Drug: intra-wound instillation of ketamine
intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure |
Placebo Comparator: control group
intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure, with closure of suction drain tube for 30 min. postoperatively.
|
Drug: intra-wound instillation of normal saline
intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
Other Name: placebo |
Active Comparator: systemic ketamine group
Intra-muscular injection of ketamine at a dose of 1 mg/kg before wound closure.
|
Drug: systemic administration of ketamine
intra-muscular administration of ketamine (1 mg/ kg), given before wound closure. |
Primary Outcome Measures :
- total opioid consumption [ Time Frame: 24 hours ]the total amount of morphine consumed during follow up period
Secondary Outcome Measures :
- first request of analgesia [ Time Frame: 24 hours ]time to first request of rescue analgesic drug
- VAS [ Time Frame: 24 hours ]effect of study drugs on postoperative pain measured by VAS score
Other Outcome Measures:
- possible side effects [ Time Frame: 24 hours ]occurrence of possible side effects during follow up
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- patients with thyroid cancer scheduled for total thyroidectomy.
Exclusion Criteria:
- BMI>35
- Unstable ischaemic cardiac disease
- Increased intracranial pressure
- Increased intraocular pressure
- Hypersensitivity or allergy to ketamine, local anesthetic, morphine, or other drugs used in the study.
- Severe psychiatric disease
- Unwillingness or inability to use PCA-device
- Inability to use VAS scale
No Contacts or Locations Provided
Responsible Party: | Ahmad Mohammad Abd El-Rahman, lecturer of anesthesia, ICU, and pain management, Assiut University |
ClinicalTrials.gov Identifier: | NCT02642497 |
Other Study ID Numbers: |
342 |
First Posted: | December 30, 2015 Key Record Dates |
Last Update Posted: | January 4, 2017 |
Last Verified: | January 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Keywords provided by Ahmad Mohammad Abd El-Rahman, Assiut University:
postoperative analgesia ketamine total thyroidectomy |
Additional relevant MeSH terms:
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Ketamine Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Anesthetics, Dissociative Anesthetics, Intravenous Anesthetics, General Anesthetics Central Nervous System Depressants Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |